Polyrizon Ltd Stock Price, News & Analysis

Polyrizon (Nasdaq: PLRZ) announced a pivotal manufacturing milestone on December 2, 2025, producing larger-scale batches of its flagship intranasal hydrogel, PL-14 Allergy Blocker, with runs meeting specifications for consistency, stability, and quality.

The successful CDMO production validates the company’s Capture & Contain™ (C&C) platform manufacturing strategy, enables supply for planned clinical trials in 2026, and supports potential future commercial scale-up. The company highlights market opportunities in seasonal allergic rhinitis (estimated USD 11.14B in 2025) and influenza markets while noting continued R&D on Trap & Target™ (T&T) for nasal drug delivery.

Polyrizon (Nasdaq: PLRZ) reported preclinical ex-vivo results on Dec 3, 2025 showing its proprietary naloxone Trap and Target (T&T) hydrogel adhered to rabbit nasal mucosa longer than a marketed intranasal naloxone spray.

In a 30-minute simulated nasal wash study using residual fluorescence quantification, the hydrogel retained significantly higher fluorescence than the commercial product (p < 0.0001, two-way ANOVA), indicating stronger mucoadhesion that may support prolonged nasal residence and potentially improved intranasal absorption.

Polyrizon (Nasdaq: PLRZ) announced the successful completion of a key manufacturing upscaling milestone for its intranasal C&C platform on Dec 2, 2025. The company and its CDMO transitioned PL-14 from small-batch lab production to a larger-scale controlled run that validated key formulation parameters and showed the PL-14 formulation can be reliably produced at increased batch volumes while maintaining quality.

The batch is intended to support clinical trial material (CTM) for a clinical trial expected to commence in 2026 and is described as produced in line with U.S. and European regulatory standards, advancing readiness for clinical and regulatory activities and potential future commercial manufacturing.

Polyrizon (Nasdaq: PLRZ) reported positive in‑vitro results for its intranasal gel candidate PL‑16 Viral Blocker on Nov 6, 2025. Tests in cell models showed broad-spectrum blocking against respiratory viruses including H1N1, with high cell viability and no cytotoxicity.

Mechanistic experiments indicated the effect is reversible and physical: virus particles recovered infectivity after the formulation was removed, showing the product forms a temporary mucosal barrier rather than pharmacologically inactivating virus. Company plans clinical studies and regulatory review.

Polyrizon (Nasdaq: PLRZ) announced positive pre-clinical results for its intranasal formulation PL-14 on October 6, 2025. The study measured penetration of the house dust mite allergen Der p 1 through a PL-14 hydrogel barrier.

Key measured results: 1.07% penetration at 1 hour, 1.14% at 2 hours and 13.6% at 4 hours. The study used allergen loads described as tens of times higher than typical real-world exposures. Polyrizon said PL-14 formed an effective nasal barrier and plans to initiate clinical studies to support regulatory and clinical pathways.

Polyrizon (NASDAQ:PLRZ) has submitted a pre-submission package to the FDA for its PL-14 Allergy Blocker, marking a significant regulatory milestone. The novel nasal spray creates a physical barrier to block allergens and provide relief from allergic rhinitis symptoms.

The comprehensive submission includes manufacturing plans, clinical development strategies, and regulatory pathways. PL-14 is designed to alleviate mild nasal irritation symptoms caused by various airborne allergens, including environmental pollens, house dust, animal hairs, and dust mites.

Polyrizon (NASDAQ:PLRZ) has reported successful preclinical results for its PL-14 Allergy Blocker, demonstrating over 60% deposition in the nasal vestibule. The study, conducted with the University of Parma, validated the product's targeted delivery mechanism using a silicone-based human nasal cast and fluorescein-labeled imaging.

The PL-14 formulation, part of Polyrizon's proprietary Capture & Contain (C&C) platform, aims to create a physical barrier against allergens before they trigger immune responses. The global allergen blocker market, valued at $0.14 billion in 2024, is projected to reach $0.21 billion by 2033, growing at a 4.4% CAGR.

Polyrizon (Nasdaq: PLRZ), a biotechnology company focused on intranasal product development, has successfully regained compliance with all Nasdaq listing requirements. The company received formal confirmation from the Nasdaq Hearings Panel's Hearings Advisor on August 13, 2025, confirming its compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).

The confirmation satisfies all previously outlined conditions by the Nasdaq Hearings Panel in their July 9, 2025 decision. As a result, Polyrizon will maintain its listing and continue trading on the Nasdaq Capital Market under the ticker symbol "PLRZ".

Polyrizon (Nasdaq: PLRZ) has announced positive preclinical results for its PL-14 Allergy Blocker, demonstrating successful intranasal delivery in a collaborative study with the University of Parma. The study showed over 60% deposition of the product in the nasal vestibule, the critical first point of contact for airborne allergens.

The research validates the company's proprietary Capture & Contain (C&C) platform, supporting its mechanism of action as a physical barrier against allergens. The global allergen blocker market, valued at $0.14 billion in 2024, is projected to reach $0.21 billion by 2033, growing at a 4.4% CAGR. The company plans to advance toward clinical trials following these encouraging preclinical results.